SPRY
ARS Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.49
−4.78%Sep 22, 2026, 05:44 UTC
The DJS Law Group reminded investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.
Source:Sep 18, 2026, 12:15 UTC
Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. on behalf of investors who acquired ARS securities between March 9, 2026 and June 24, 2026, with a lead plaintiff deadline of October 5, 2026.
Sep 15, 2026, 13:20 UTC
A securities class action lawsuit was filed against ARS Pharmaceuticals, Inc. in the U.S. District Court for the Southern District of California on behalf of investors who purchased more than $100,000 of its shares between March 9, 2026 and June 24, 2026, with a deadline of October 5, 2026.
Aug 16, 2026, 13:55 UTC
ARS Pharmaceuticals announced the appointment of Meg Smith as Chief Commercial Officer, effective August 17.
Source:Aug 13, 2026, 20:01 UTC
ARS Pharmaceuticals reported second quarter 2026 financial results, including $26.2 million in U.S. neffy net product revenue and a 5% total U.S. epinephrine market share for Type 1 allergies, with 8% share within field-targeted accounts.
Aug 10, 2026, 08:44 UTC
ARS Pharmaceuticals, Inc. was sued in a class action lawsuit for alleged securities law violations under the Securities Exchange Act of 1934, with the DJS Law Group reminding investors of the case and inviting lead plaintiff appointments.
Aug 6, 2026, 16:06 UTC
A shareholder class action lawsuit was filed against ARS Pharmaceuticals, Inc., alleging false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray neffy with CVS Caremark.
Jul 7, 2026, 20:30 UTC
Richard Lowenthal is transitioning from his role as CEO of ARS Pharmaceuticals after more than a decade of leadership since co-founding the company.
Jun 28, 2026, 15:54 UTC
The Schall Law Firm announced an investigation into ARS Pharmaceuticals, Inc. for potential securities law violations after its stock dropped sharply on June 24, 2026, following news that Neffy failed to secure new formulary additions.
Jun 25, 2026, 14:04 UTC
CVS Caremark declined to add ARS Pharmaceuticals' epinephrine spray Neffy to its formulary.
Source: